This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Pilot Study of EM-1421 for the Treatment of Cervical Intraepithelial Neoplasia

This study has been completed.
University of Maryland, Baltimore County
Planned Parenthood Delaware (Wilmington, DE)
Information provided by (Responsible Party):
Erimos Pharmaceuticals Identifier:
First received: September 8, 2005
Last updated: February 20, 2016
Last verified: August 2006
The primary objective of this study is to determine pilot safety and efficacy data for a topical formulation of EM-1421 applied to the cervix of patients with CIN 1, 2, or 3.

Condition Intervention Phase
Cervical Intraepithelial Neoplasia Drug: EM-1421 Phase 1 Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Pilot Translational Study of Tetra-O-Methyl Nordihydroguaiaretic Acid (EM-1421) for the Treatment of Cervical Intraepithelial Neoplasia Induced by Human Papilloma Virus

Resource links provided by NLM:

Further study details as provided by Erimos Pharmaceuticals:

Enrollment: 8
Study Start Date: November 2004
Study Completion Date: December 2006
Primary Completion Date: April 2006 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: EM-1421

Administration of EM-1421 intravaginally once per week for 3 weeks

Dose level of 45 mg/application (1% w/w) or 90 mg/application (2% w/w)

Drug: EM-1421
EM-1421 administered intravaginally every 3 weeks as 45 mg (1% w/w) EM-1421 or 90 mg (2% w/w) EM-1421
Other Names:
  • Terameprocol
  • M4N
  • Tetra-O-Methyl Nordihydroguaiaretic Acid

Detailed Description:
This was an open-label, pilot Phase I/II dose evaluation and pharmacokinetic evaluation study to compare the safety and efficacy of terameprocol (45mg or 90mg/application)administered once per week for 3 weeks to the cervix uteri in patients with biopsy-proven CIN. Patients who met eligibility criteria visited the clinic weekly for terameprocol application. Patients kept a daily diary card record of genitourinary symptoms.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 18 years of age or older
  • Negative pregnancy test
  • Biopsy confirmed CIN 1, 2, or 3

Exclusion Criteria:

  • Pregnancy or breast feeding
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00154089

United States, Maryland
University of Maryland, Dept. of Family Medicine
Baltimore, Maryland, United States, 21201
Sponsors and Collaborators
Erimos Pharmaceuticals
University of Maryland, Baltimore County
Planned Parenthood Delaware (Wilmington, DE)
  More Information

Responsible Party: Erimos Pharmaceuticals Identifier: NCT00154089     History of Changes
Other Study ID Numbers: EM-1421 #201
Study First Received: September 8, 2005
Last Updated: February 20, 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by Erimos Pharmaceuticals:
cervical intraepithelial neoplasia

Additional relevant MeSH terms:
Carcinoma in Situ
Cervical Intraepithelial Neoplasia
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Molecular Mechanisms of Pharmacological Action
Protective Agents
Physiological Effects of Drugs
Lipoxygenase Inhibitors
Enzyme Inhibitors
Cyclooxygenase Inhibitors
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Anti-Inflammatory Agents
Antirheumatic Agents processed this record on September 21, 2017